<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T13:43:06Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/178642" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/178642</identifier><datestamp>2025-12-05T12:33:31Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478916</setSpec><setSpec>col_2072_478917</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>RAD51D Aberrant Splicing in Breast Cancer: Identification of Splicing Regulatory Elements and Minigene-Based Evaluation of 53 DNA Variants</dc:title>
   <dc:creator>Bueno Martínez, Elena</dc:creator>
   <dc:creator>Sanoguera Miralles, Lara</dc:creator>
   <dc:creator>Valenzuela Palomo, Alberto</dc:creator>
   <dc:creator>Lorca, Víctor</dc:creator>
   <dc:creator>Gómez Sanz, Alicia</dc:creator>
   <dc:creator>Carvalho, Sara</dc:creator>
   <dc:creator>Allen, Jamie</dc:creator>
   <dc:creator>Infante, Mar</dc:creator>
   <dc:creator>Pérez Segura, Pedro</dc:creator>
   <dc:creator>Lázaro García, Conxi</dc:creator>
   <dc:creator>Easton, Douglas F.</dc:creator>
   <dc:creator>Devilee, Peter</dc:creator>
   <dc:creator>Vreeswijk, Maaike P. G.</dc:creator>
   <dc:creator>Hoya, Miguel de la</dc:creator>
   <dc:creator>Velasco, Eladio A.</dc:creator>
   <dc:subject>Càncer de mama</dc:subject>
   <dc:subject>Càncer d'ovari</dc:subject>
   <dc:subject>Breast cancer</dc:subject>
   <dc:subject>Ovarian cancer</dc:subject>
   <dcterms:abstract>RAD51D loss-of-function variants increase lifetime risk of breast and ovarian cancer. Splicing disruption is a frequent pathogenic mechanism associated with variants in susceptibility genes. Herein, we have assessed the splicing and clinical impact of splice-site and exonic splicing enhancer (ESE) variants identified through the study of similar to 113,000 women of the BRIDGES cohort. A RAD51D minigene with exons 2-9 was constructed in splicing vector pSAD. Eleven BRIDGES splice-site variants (selected by MaxEntScan) were introduced into the minigene by site-directed mutagenesis and tested in MCF-7 cells. The 11 variants disrupted splicing, collectively generating 25 different aberrant transcripts. All variants but one produced negligible levels (&lt;3.4%) of the full-length (FL) transcript. In addition, ESE elements of the alternative exon 3 were mapped by testing four overlapping exonic microdeletions (>= 30-bp), revealing an ESE-rich interval (c.202_235del) with critical sequences for exon 3 recognition that might have been affected by germline variants. Next, 26 BRIDGES variants and 16 artificial exon 3 single-nucleotide substitutions were also assayed. Thirty variants impaired splicing with variable amounts (0-65.1%) of the FL transcript, although only c.202G>A demonstrated a complete aberrant splicing pattern without the FL transcript. On the other hand, c.214T>C increased efficiency of exon 3 recognition, so only the FL transcript was detected (100%). In conclusion, 41 RAD51D spliceogenic variants (28 of which were from the BRIDGES cohort) were identified by minigene assays. We show that minigene-based mapping of ESEs is a powerful approach for identifying ESE hotspots and ESE-disrupting variants. Finally, we have classified nine variants as likely pathogenic according to ACMG/AMP-based guidelines, highlighting the complex relationship between splicing alterations and variant interpretation.</dcterms:abstract>
   <dcterms:issued>2021-06-25T10:46:24Z</dcterms:issued>
   <dcterms:issued>2021-06-25T10:46:24Z</dcterms:issued>
   <dcterms:issued>2021-06-07</dcterms:issued>
   <dcterms:issued>2021-06-25T09:14:44Z</dcterms:issued>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:relation>Reproducció del document publicat a: https://doi.org/10.3390/cancers13112845</dc:relation>
   <dc:relation>Cancers, 2021, vol. 13, num. 11</dc:relation>
   <dc:relation>https://doi.org/10.3390/cancers13112845</dc:relation>
   <dc:relation>info:eu-repo/grantAgreement/EC/H2020/634935/EU//BRIDGES</dc:relation>
   <dc:rights>cc by (c) Bueno Martínez et al., 2021</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:publisher>MDPI</dc:publisher>
   <dc:source>Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))</dc:source>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>